LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Edwards Lifesciences Corp

Geschlossen

BrancheGesundheitswesen

77.57 -0.12

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

76.74

Max

77.74

Schlüsselkennzahlen

By Trading Economics

Einkommen

-28M

358M

Verkäufe

27M

1.4B

KGV

Branchendurchschnitt

32.273

51.198

EPS

0.64

Gewinnspanne

25.342

Angestellte

15,800

EBITDA

-50M

434M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+5.82% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.1B

46B

Vorheriger Eröffnungskurs

77.69

Vorheriger Schlusskurs

77.57

Nachrichtenstimmung

By Acuity

39%

61%

126 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Edwards Lifesciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Juli 2024, 13:57 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences to Buy Innovalve for $300 Million

25. Okt. 2024, 09:10 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

25. Okt. 2024, 08:35 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

3. Sept. 2024, 20:38 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences: After Recent Accelerated Repurchase Agreement and August Buybacks Via 10b5-1 Agreement and Open Market Repurchases, Company Has $1.4B in Remaining Authorization

3. Sept. 2024, 20:37 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences Completes Sale of Critical Care Group to Becton Dickinson for $4.2B

3. Sept. 2024, 20:36 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences Authorizes $1.5B of Additional Share Repurchases

25. Juli 2024, 09:02 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Thursday: Ford, IBM, Chipotle, American Airlines -- WSJ

25. Juli 2024, 08:40 UTC

Top News

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

24. Juli 2024, 20:17 UTC

Ergebnisse

Edwards Lifesciences: Expects 2024 Edwards Sales Growth of 8% to 10% >EW

24. Juli 2024, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

24. Juli 2024, 20:15 UTC

Ergebnisse

Edwards Lifesciences 2Q Sales $1.39B >EW

24. Juli 2024, 20:15 UTC

Ergebnisse

Edwards Lifesciences 2Q Net $366.3M >EW

24. Juli 2024, 20:15 UTC

Ergebnisse

Edwards Lifesciences 2Q Adj EPS 70c >EW

24. Juli 2024, 20:15 UTC

Ergebnisse

Edwards Lifesciences 2Q EPS 61c >EW

15. Juli 2024, 13:42 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences to Buy Innovalve for $300M

15. Juli 2024, 13:01 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences: SAPIEN M3 Remains on Track to Become First Approved Transfemoral TMVR System in Europe by End of 2025 >EW

15. Juli 2024, 13:01 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences: Acquisition Enhances TMVR Technologies to Address Large Unmet Structural Heart Patient Needs >EW

15. Juli 2024, 13:00 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences to Acquire Innovalve Bio Medical Ltd., Early-Stage Transcatheter Mitral Valve Replacement Co >EW

15. Juli 2024, 13:00 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences To Acquire Innovalve >EW

Peer-Vergleich

Kursveränderung

Edwards Lifesciences Corp Prognose

Kursziel

By TipRanks

5.82% Vorteil

12-Monats-Prognose

Durchschnitt 82.3 USD  5.82%

Hoch 95 USD

Tief 75 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Edwards Lifesciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

7

Buy

8

Halten

0

Sell

Technischer Score

By Trading Central

74.52 / 75.54Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

126 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.